12 results on '"Di Bona E"'
Search Results
2. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia
- Author
-
DI BONA, E., Avvisati, G., Castaman, G., Vegna, Ml, DE SANCTIS, Vitaliana, Rodeghiero, F., and Mandelli, Franco
- Subjects
Adult ,Male ,Time Factors ,Adolescent ,Antineoplastic Agents ,Hemorrhage ,Tretinoin ,Leukemia, Promyelocytic, Acute ,Humans ,Prospective Studies ,Child ,Aged ,Antibiotics, Antineoplastic ,Platelet Count ,Incidence ,Remission Induction ,Fibrinogen ,Infant ,Middle Aged ,Italy ,Evaluation Studies as Topic ,Child, Preschool ,Multivariate Analysis ,Drug Therapy, Combination ,Female ,Morbidity ,Idarubicin - Abstract
A total of 622 consecutive patients with acute promyelocytic leukaemia (APL) treated within the Gruppo Italiano per le Malattie Ematologiche dell'Adulto (GIMEMA) group during 1989-97 have been reviewed to assess the clinical effectiveness of all-trans retinoic acid (ATRA) on the incidence of early haemorrhagic deaths and on APL-associated coagulopathy. Of them, 499 were treated with idarubicin plus ATRA (study A) and 123 with Idarubicin alone (study B). In both studies, similar guidelines for supportive treatment were used. Haemorrhagic symptoms were evaluated according to a reproducible score system. Deaths occurring within 10 d of starting treatment were 19 (3.8%) in study A and nine (7.3%) in study B (P = 0.09), with 15 (3%) and five (4.1%) (P not significant) due to haemorrhage. Overall, induction mortality was 7.6% and 16.2% respectively (P0.003). In study A, days with platelet counts/= 20 x 109/l or with fibrinogen/= 1 g/L were reduced by about 30%, the haemorrhagic score by 50% and the consumption of blood products by about 40%, and fewer patients were treated with antihaemorrhagic drugs (39% vs. 61%; P0.001). On multivariate analysis, early deaths were influenced by blast count at diagnosis30 x 109/l (P0.001) in both studies, and by a haemorrhagic score of 3 in study A (P0.001). Although the reduction of early fatal haemorrhages was not significant, a substantial clinical improvement was evident in terms of reduction of the severity of bleeding symptoms, blood product consumption and overall induction mortality when ATRA was combined with idarubicin.
- Published
- 2000
3. The long-acting anti-C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab.
- Author
-
Sica M, Barone F, Nannelli C, Ricci P, Marano L, De Angioletti M, Di Bona E, Risitano AM, and Notaro R
- Subjects
- Humans, Antibodies, Monoclonal, Humanized pharmacology, Antibodies, Monoclonal, Humanized therapeutic use, Hemolysis, Erythrocytes, Hemoglobinuria, Paroxysmal drug therapy
- Published
- 2023
- Full Text
- View/download PDF
4. COVID-19 in patients with paroxysmal nocturnal haemoglobinuria: an Italian multicentre survey.
- Author
-
Barcellini W, Fattizzo B, Giannotta JA, Quattrocchi L, Aydin S, Barone F, Carbone C, Pomponi F, Metafuni E, Beggiato E, Sica S, Di Bona E, Lanza F, Notaro R, and Iori AP
- Subjects
- Adult, Anemia, Aplastic complications, COVID-19 epidemiology, Female, Humans, Italy epidemiology, Male, Middle Aged, Myelodysplastic Syndromes complications, SARS-CoV-2 isolation & purification, COVID-19 complications, Hemoglobinuria, Paroxysmal complications
- Published
- 2021
- Full Text
- View/download PDF
5. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
- Author
-
Sanford D, Lo-Coco F, Sanz MA, Di Bona E, Coutre S, Altman JK, Wetzler M, Allen SL, Ravandi F, Kantarjian H, and Cortes JE
- Subjects
- Adult, Aged, Antineoplastic Agents adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Arsenic Trioxide, Arsenicals administration & dosage, Arsenicals therapeutic use, Benzoates adverse effects, Biomarkers, Tumor blood, Cardiovascular Diseases chemically induced, Cell Differentiation drug effects, Combined Modality Therapy, Consolidation Chemotherapy, Disease-Free Survival, Drug Resistance, Neoplasm, Febrile Neutropenia chemically induced, Female, Hematopoietic Stem Cell Transplantation, Humans, Kaplan-Meier Estimate, Leukemia, Promyelocytic, Acute blood, Leukemia, Promyelocytic, Acute therapy, Male, Middle Aged, Oncogene Proteins, Fusion blood, Oxides administration & dosage, Oxides therapeutic use, Recurrence, Remission Induction, Salvage Therapy, Tetrahydronaphthalenes adverse effects, Tretinoin administration & dosage, Tretinoin therapeutic use, Antineoplastic Agents therapeutic use, Benzoates therapeutic use, Leukemia, Promyelocytic, Acute drug therapy, Tetrahydronaphthalenes therapeutic use
- Abstract
Treatment of acute promyelocytic leukaemia (APL) with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) is highly effective first-line therapy, although approximately 5-10% of patients relapse. Tamibarotene is a synthetic retinoid with activity in APL patients who relapse after chemotherapy and ATRA, but has not been studied in relapse after treatment with ATO and ATRA. We report on a phase II study of tamibarotene in adult patients with relapsed or refractory APL after treatment with ATRA and ATO (n = 14). Participants were treated with tamibarotene (6 mg/m(2) /d) during induction and for up to six cycles of consolidation. The overall response rate was 64% (n = 9), the rate of complete cytogenetic response was 43% (n = 6) and the rate of complete molecular response was 21% (n = 3). Relapse was frequent with 7 of 9 responders relapsing after a median of 4·6 months (range 1·6-26·8 months). The median event-free survival (EFS) was 3·5 months [95% confidence interval (CI) 0-8·6 months] and the median overall survival (OS) was 9·5 months (95% CI 5·9-13·1 months). These results demonstrate that tamibarotene has activity in relapsed APL after treatment with ATO and ATRA and further studies using tamibarotene as initial therapy and in combination with ATO are warranted., (© 2015 John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
6. Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia - very long follow-up.
- Author
-
Rohatiner AZ, Smith ML, Spinelli O, Rambaldi A, Bassan R, di Bona E, Rodeghiero F, Raimondi R, Björkholm M, Johnson S, Newland AC, Cavenagh JD, Macdougall F, Waters R, Fitzgibbon J, Barbui T, and Lister A
- Subjects
- Adult, Autografts, Disease-Free Survival, Female, Follow-Up Studies, History, Ancient, Humans, Male, Middle Aged, Remission Induction, Survival Rate, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Consolidation Chemotherapy methods, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute therapy, Transplantation Conditioning
- Published
- 2014
- Full Text
- View/download PDF
7. A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes.
- Author
-
Intermesoli T, Delaini F, Acerboni S, Salmoiraghi S, Spinelli O, Guerini V, Vannucchi AM, Mappa S, Rossi G, Rossi V, Di Bona E, Paratore S, Carobbio A, Rambaldi A, Barbui T, and Bassan R
- Subjects
- Adult, Aged, Benzamides, Dose-Response Relationship, Drug, Drug Administration Schedule, Eosinophils pathology, Female, Gene Rearrangement, Humans, Hypereosinophilic Syndrome genetics, Imatinib Mesylate, Leukocyte Count, Male, Middle Aged, Oncogene Proteins, Fusion genetics, Piperazines therapeutic use, Pyrimidines therapeutic use, Receptor, Platelet-Derived Growth Factor alpha genetics, Treatment Outcome, Young Adult, mRNA Cleavage and Polyadenylation Factors genetics, Hypereosinophilic Syndrome drug therapy, Piperazines administration & dosage, Pyrimidines administration & dosage
- Abstract
Although imatinib may be effective in hypereosinophilic syndromes, the exact response kinetics are not known. Imatinib was administered at 100-400 mg/d each week in a 12-week response-oriented schedule, targeting a complete clinical and haematological remission (CR). CR was achieved in 11/23 patients (6/6 with FIP1L1-PDGRFA rearrangement and 5/17 without, P = 0.006), most after 2 weeks of 100 mg/d imatinib. The maximum imatinib dose had no effect in early unresponsive patients. Low-dose, short-course imatinib may represent a rational choice for identifying responsive cases, both within and outside the pre-defined FIP1L1 rearrangement subset.
- Published
- 2009
- Full Text
- View/download PDF
8. Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia.
- Author
-
Pagana L, Pulsoni A, Tosti ME, Avvisati G, Mele L, Mele M, Martino B, Visani G, Cerri R, Di Bona E, Invernizzi R, Nosari A, Clavio M, Allione B, Coser P, Candoni A, Levis A, Camera A, Melillo L, Leone G, and Mandelli F
- Subjects
- Acute Disease, Adolescent, Adult, Aged, Aged, 80 and over, Cytogenetic Analysis, Female, Follow-Up Studies, Genetic Predisposition to Disease, Humans, Incidence, Leukemia, Myeloid mortality, Leukemia, Myeloid therapy, Male, Middle Aged, Neoplasms, Second Primary mortality, Neoplasms, Second Primary therapy, Odds Ratio, Remission Induction, Breast Neoplasms mortality, Breast Neoplasms therapy, Hodgkin Disease mortality, Hodgkin Disease therapy, Leukemia, Myeloid epidemiology, Lymphoma mortality, Lymphoma therapy, Neoplasms, Second Primary epidemiology
- Abstract
Between July 1992 and June 1996, 3934 new cases of acute leukaemia were registered in the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Archive of Adult Acute Leukaemia. Two hundred cases (5.1%) presented with a history of primary malignancy (PM), 179 of which were acute myeloid leukaemia (AML). The median age of these cases was significantly higher than that of other primitive AML (63 years vs. 57 years; P < 0.001). The number of men was significantly lower than the number of women [74/1544 (4.8%) vs. 105/1420 (7.4%); odds ratio (OR) 0.63, 95% confidence interval (CI) 0.46-0.87; P < 0.002], as was the number of patients aged <65 years [104/1963 (5.3%) vs. 75/1001 (7.5%); OR 0.69, 95% CI 0.50-0.95; P < 0.01]. An increased incidence of cancer was observed among first-degree relatives of patients with AML occurring after a PM (secondary AML; sAML) [66/179 (36.9%) sAML vs. 757/2785 (27.2%) de novo AML, age adjusted; OR 2.62, 95% CI 1.07-6.42; P < 0.005]. Prevalent types of PM were breast cancer, lymphoma and Hodgkin's disease. sAML occurred after a median latency of 52 months (range 2-379). Of the 122 patients who received chemotherapy for sAML, 67 patients (55%) achieved a complete remission (CR), three a partial remission, 15 (12%) died in induction and 37 (30%) were unresponsive. The median duration of CR was 30 weeks (range 4-250). The median overall survival was 7 months (range 1-196). Comparing acute promyelocytic leukaemia with all other French-American-British (FAB) groups, a significant increase in CR achievement was observed [14/18 (77.7%) vs. 53/101 (52.4%), P < 0.046] as well as in median CR duration (55 vs. 24 months, P < 0.02). The analysis of our data suggests that not only previous chemotherapy but also genetic predisposition could play a role in the pathogenesis of sAML.
- Published
- 2001
- Full Text
- View/download PDF
9. Characterization of 12p molecular events outside ETV6 in complex karyotypes of acute myeloid malignancies.
- Author
-
La Starza R, Stella M, Testoni N, Di Bona E, Ciolli S, Marynen P, Martelli MF, Mandelli F, and Mecucci C
- Subjects
- Adult, Aged, Chromosome Breakage genetics, Chromosomes, Human, Pair 12, Female, Gene Rearrangement genetics, Humans, In Situ Hybridization, Fluorescence, Karyotyping, Male, Middle Aged, Translocation, Genetic genetics, Leukemia, Myeloid genetics
- Abstract
Acute myeloid disorders with rearrangements of 12p outside the ETV6 gene were characterized by fluorescence in situ hybridization (FISH) with a panel of DNA probes. Seven patients with de novo acute myeloid leukaemia (AML), one with secondary acute myeloid leukaemia (sAML), and one in the blast phase of chronic myeloid leukaemia (CML-BP) were enrolled in the study. All AML cases showed multiple karyotypic changes. Chromosome 5 and/or 7 deletions were the most frequent accompanying changes. FISH revealed amplification, cryptic translocation, and fragmentation of chromosome 12, not discernible at karyotypic level. Different karyotypic rearrangements of 12p showed a common molecular event. Among the seven cases in which breakpoints could be determined, six were telomeric and one centromeric to ETV6. In three AML cases a new recurrent breakpoint in the telomeric region was identified distally to locus D12S158 and to pac 922B22 which is the most telomeric probe available for 12p. Accompanying cryptic deletions were also detected in five patients and the commonly deleted region, of around 700 kb, included the ETV6 gene and the D12S391 locus.
- Published
- 1999
- Full Text
- View/download PDF
10. Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukaemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
- Author
-
Pagano L, Pulsoni A, Tosti ME, Annino L, Mele A, Camera A, Martino B, Guglielmi C, Cerri R, Di Bona E, Invernizzi R, Castagnola C, Bassan R, Mele L, Todeschini G, Leone G, and Mandelli F
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Italy epidemiology, Male, Middle Aged, Neoplasms, Second Primary epidemiology, Precursor Cell Lymphoblastic Leukemia-Lymphoma epidemiology
- Abstract
Between July 1992 and June 1996, 901 new cases of adult acute lymphoblastic leukaemia were recorded in the GIMEMA Archive of Adult Acute Leukaemia; 21 of them (2.3%) had a previous primary malignancy (PM). We found that secondary acute lymphoblastic leukaemia cases (sALL) presented with older age, a high incidence of pre-pre-B immunophenotype and a significantly higher prevalence of cancer among relatives compared to de novo ALL. The leukaemogenic activity of the cytotoxic drugs employed for the treatment of PM may have played a potential role in only a proportion of patients, opening the possibility that some sALL patients may have developed two or more malignancies due to individual predisposing factors.
- Published
- 1999
- Full Text
- View/download PDF
11. Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia.
- Author
-
Bassan R, Lerede T, Di Bona E, Rambaldi A, Rossi G, Pogliani E, Oriani A, D'Emilio A, Izzi T, Lambertenghi-Deliliers G, Corneo G, and Barbui T
- Subjects
- Adolescent, Adult, Asparaginase administration & dosage, Disease-Free Survival, Female, Humans, Idarubicin administration & dosage, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Prednisolone administration & dosage, Remission Induction, Risk Factors, Transplantation, Homologous, Treatment Outcome, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Marrow Transplantation methods, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
- Abstract
Between 1991 and 1993 we conducted a collaborative trial in adult acute lymphoblastic leukaemia, introducing an idarubicin (IDA)-containing regimen for induction and early consolidation, and increasing consolidation intensity with an autologous bone marrow transplantation phase (ABMT, patients aged <51 years) followed by further chemotherapy for 12 weeks and low-dose maintenance for 6 months (ABMT patients) or 18 months. 96 patients were evaluable for antileukaemic response after induction with vincristine-prednisone-L-asparaginase plus cumulative IDA 36 or 20 mg/m2 (IVAP-1 and IVAP-2), and for disease-free survival (DFS) after a minimum follow-up >3.5 years with an off-therapy interval >1.5 years. The response rate was 44% (7/16) with IVAP-1 and 90% (72/80) with IVAP-2 (P=0.0001), due to regimen-related toxicities. Post-remission therapy was administered as planned to most cases but protocol violation was registered in some patients eligible to ABMT and post-graft chemotherapy. The 5-year disease-free survival (DFS) rate was 31%. Multivariate analysis indicated that DFS was improved in patients receiving a transplant (11 allogeneic, DFS 70%; 32 ABMT, 36%; 37 neither, 17%; P < 0.001) and was negatively affected by high-risk features such as blast cell count >25x10(9)/l, T-cell or mature B-cell immunophenotype, and t(9;22)/t(4;11) (all P values <0.05). The 5-year DFS rate was 54% for 26 patients with no high-risk factor, 26% for 35 patients with any one, and 6% for 18 patients with any two (P<0.005). IVAP-2 brought about a high complete response rate and post-remission treatment including ABMT was feasible and modestly toxic. In spite of the short post-graft chemotherapy phase, the long-term DFS rate was good in cases with no high-risk feature. However, because autografting may be redundant in the standard-risk category, its role requires further investigation for high-risk cases.
- Published
- 1999
- Full Text
- View/download PDF
12. A (15;17) translocation not associated with acute promyelocytic leukaemia.
- Author
-
Di Bona E, Montaldi A, Guercini N, Rossi V, Luciano A, Biondi A, and Rodeghiero F
- Subjects
- Adult, Drug Resistance, Neoplasm, Female, Humans, In Situ Hybridization, Fluorescence, Karyotyping, Polymerase Chain Reaction, Chromosomes, Human, Pair 15, Chromosomes, Human, Pair 17, Leukemia, Promyelocytic, Acute genetics, Translocation, Genetic
- Abstract
We report a woman with acute myeloid leukaemia (AML) type M2 according to FAB classification, showing a t(15;17) apparently identical to that of acute promyelocytic leukaemia (APL) on conventional cytogenetic analysis. Fluorescence in situ hybridization (FISH) using cosmidic probes specific for RAR alpha and PML, regions did not show a fusion signal as in APL. The breakpoints were assigned to 15q24.3 and 17q21.1. Detailed molecular analyses did not reveal any involvement of RAR alpha and PML genes. The patient was resistant to several front-line AMI treatments and to all-trans retinoic acid (ATRA). These findings reinforce FISH and RT-PCR as useful tools for the characterization of a t(15;17) as the translocation specifically associated with APL.
- Published
- 1996
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.